Findings from an accepted manuscript published in the American Journal of Roentgenology (AJR) suggest that for patients with dense breasts undergoing screening in the incidence setting, a commercial AI tool did not provide additional benefit to mammography with supplementary ultrasound (US).

57-YO woman with dense breasts—screening mammography (not shown) assessed BI-RADS 2. a. Supplementary screening breast ultrasound performed on same day as mammogram shows 4-mm round hypoechoic mass with angular margins in right upper medial breast. b. Screenshot of output of AI tool. Tool assigned abnormality score of “low” in each breast. Ultrasound-guided core biopsy and surgery revealed invasive ductal carcinoma, not otherwise specified (Luminal A, histologic grade I). Case represents false-negative AI result. 


July 28, 2023 — Findings from an accepted manuscript published in the American Journal of Roentgenology (AJR) suggest that for patients with dense breasts undergoing screening in the incidence setting, a commercial AI tool did not provide additional benefit to mammography with supplementary ultrasound (US). 

“Mammography with supplementary ultrasound showed higher accuracy, higher specificity, and lower recall rate in comparison to mammography with AI, as well as in comparison to mammography with both US and AI,” wrote corresponding author Hee Jung Moon, MD, PhD, from the department of radiology at South Korea’s Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine. 

This AJR accepted manuscript included 1,325 women (mean age, 53 years) with dense breasts who underwent both screening mammography and supplementary breast US within a 1-month interval from January 2017 to December 2017; prior mammogram and US were available to compare in 91.2% and 91.8%, respectively. Fifteen radiologists (5 staff and 10 fellows) interpreted mammography and US examinations, and clinical reports were used for Moon et al.’s analysis. A commercially available AI algorithm (Lunit INSIGHT, v 1.1.0.0, Seoul, Korea) was used to retrospectively evaluate mammographic examinations for cancer presence. Then, screening performances were compared among mammography, AI, US, and test combinations, using generalized estimating equations. At least 24 months of imaging stability was required for a benign diagnosis. 

Ultimately, mammography with AI, mammography with US, and mammography with both ultrasound and AI showed recall rate of 14.9, 11.7, and 21.4 (all p < .05); sensitivity of 83.3%, 100.0%, and 100.0% (all p > .05); specificity of 85.8%, 89.1%, and 79.4% (all p < .05); and accuracy of 85.7%, 89.2%, and 79.5% (all p < .05). 

For more information: www.arrs.org 


Related Content

News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
Subscribe Now